Abstract:We read with interest the study by Boursier et al. titled “A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis” recently published in the Journal.[1] Boursier J. de Ledinghen V. Leroy V. Anty R. Francque S. Salmon D. et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017; 66: 1158-1165 Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar Using liver biopsy as reference in a cross-sectional study, the authors developed a stepwise algorithm for the detection of advanced liver fibrosis. This algorithm comprised of a first-line test called easy liver fibrosis test (eLIFT), followed by a second-line test of FibroMeter plus vibration controlled transient elastography (FMVCTE). When tested in a longitudinal cohort of 1,275 patients, the eLIFT-FMVCTE algorithm showed promising prognostic performance. This algorithm provides a potential method to extend the detection of advanced liver fibrosis to all chronic liver disease patients and to reduce unnecessary referrals of patients without significant fibrosis to hepatologists. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosisJournal of HepatologyVol. 66Issue 6PreviewChronic liver diseases (CLD) are very common: worldwide, an estimated 160 million people have chronic hepatitis C [1], 240 million have chronic hepatitis B [2], and 25% of the general population has non-alcoholic fatty liver disease (NAFLD) [3]. CLD can lead to a progressive accumulation of fibrosis in the liver which progressively evolves to cirrhosis and its life-threatening complications such as hepatocellular carcinoma (HCC), liver failure, variceal bleeding, or renal insufficiency. In 2012, driven by the growing worldwide burden of CLD, cirrhosis was responsible for more than 35 million years of lost life and thus became the eleventh leading cause of mortality among non-communicable diseases [4]. Full-Text PDF Reply to: “Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FMVCTE algorithm” and to “Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes”Journal of HepatologyVol. 68Issue 3PreviewScreening of advanced liver fibrosis: one step at a time Full-Text PDF

Early screening for chronic liver disease: impact of a FIB-4 first integrated care pathway to identify patients with significant fibrosis

Using the FIB-4, automatically calculated, followed by the ELF test in second line to screen primary care patients for liver disease

FIB-4 and Severe Liver Disease Outcomes in Primary Care: A Stratified Cox Analysis

Screening for advanced liver disease incorporating the use of transitional elastography in primary care

Non‐invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population

Automated Fibrosis-4 Index: Simplifying Non-Alcoholic Fatty Liver Disease for Diabetologists

Pitfalls in the Non-Invasive Assessment of Liver Fibrosis with Elift-Fmvcte Algorithm

[Population screening for hepatic fibrosis : who to screen, why and how ?]

Screening patients in general practice for advanced chronic liver disease using an innovative IT solution: The Liver Toolkit

Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting

Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension

Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B.

Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study

Fibrosis-4 score for screening of metabolic dysfunction-associated steatotic liver disease (MASLD): Data from a population-based sample in Tuscany

The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool?

Screening for liver fibrosis: lessons from colorectal and lung cancer screening

Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients

Cost‐effectiveness study of FIB‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at‐risk population

FIB-4 Reliability in Patients With Severe Obesity: Lower Cutoffs Needed?